Lonza CEO to step down in 2020
pharmafile | November 12, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Lonza, appointment
It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to step down from the role early next year.
The company said that Funk’s decision was based on personal reasons, and that he will leave the firm in January 2020. It was also revealed by the Board of Directors that the vacated role will be covered by Chairman Albert Baehny on an interim basis until a permanent successor is found and installed.
Furthermore, Board Member Christoph Maeder was appointed by the Board to serve as Lead Independent Director, “for reasons of good governance”.
“Albert has agreed to lead the company on a temporary basis until a successor is in place, for which a search has commenced,” remarked Maeder. “The Board respects Marc’s decision and would like to thank him for his service to Lonza and wish him well for his future endeavours.”
Baehny added: “I am committed to Lonza, its employees and all its stakeholders and I will ensure that I work in their best interests in the months ahead. The company has an exciting future in dynamic markets and I am keen to ensure that we maintain our momentum and capture all the opportunities available to us. I look forward to working with colleagues, customers, partners and other stakeholders in the coming months and also to working with the Board in the search for a new Chief Executive Officer to lead the company in the years ahead.”
Funk originally joined the company in 2008 from Merck Serono as Chief Legal and Compliance Officer, and also served as Board Secretary between 2012 and 2014. Prior to his time with Lonza, Funk co-founded biotech firm GeneProt, at which he served as co-CEO and General Counsel.
Related Content
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
Lonza to acquire Synaffix to strengthen ADC development
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has …
